Bioral® Technology

Bioral® is a novel drug delivery system, based upon cochleate technology. Bioral® encapsulates and protects a drug without chemically bonding to it and may facilitate oral dosing of drugs that typically need to be given by intravenous administration. Alternating layers of lipids spiral around a drug molecule, encapsulating it and potentially protecting it from degradation by acid or digestive enzymes in the stomach. The Bioral® technology is being evaluated as a new means of overcoming the poor oral absorption of drugs, such as the antifungal drug Amphotericin B and in programs involving siRNAs. Several pre-clinical studies have demonstrated the potential value of agents delivered using the Bioral® technology.1, 2, 3

The Bioral® drug delivery technology was developed in collaboration with the University of Albany and the University of New Jersey Medical and Dental School, each of which has granted BDSI® exclusive worldwide licenses under applicable patents. Collaboration with the National Institutes of Health has supported, in part, the Bioral® preclinical program, and a collaboration with the Walter Reed Army Institute of Research is currently exploring the use of Bioral® technology in difficult to treat parasitic infections.

1 Campo, et al. Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl-s-Triazole Derivative in a Murine Model of Graft-Versus-Host Disease. Transplantation, Vol 86, Number 1, July 15, 2008.

2 Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Perlin DS.  Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother. 2002 Aug;46(8):2704-7.

3 Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, Perlin DS.  Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother. 2000 Sep;44(9):2356-60.